MedTrace Logo

ROTEM-based Optimization of Anticoagulation Regimens in Lung Transplantation

NCT06779162 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2025-01-16

No results posted yet for this study

Summary

Extracorporeal membrane oxygenation (ECMO) is now a standard component of intraoperative support during lung transplantation, requiring anticoagulation management, typically with unfractionated heparin (UFH). While monitoring methods such as Activated Partial Thromboplastin Time (aPTT), Activated Partial Thromboplastin Time Ratio (aPTTr), Anti-Factor Xa Activity (anti-Xa), and Activated Clotting Time (ACT) are commonly used, a reliable bedside method remains elusive due to the unreliability of ACT at low UFH doses. This study evaluates the correlation among these monitoring methods and investigates the potential of the ROTEM Clotting Time INTEM/HEPTEM ratio (I/Hr) as a bedside alternative.

Conditions

  • Anticoagulation
  • Lung Transplantation
  • Viscoelastic Properties
  • Unfractionated Heparin

Sponsors & Collaborators

  • University Hospital, Motol

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06779162 on ClinicalTrials.gov